Cannabis is useful and safe in epilepsy
"Many of my patients with poorly controlled seizures have tried cannabidiols. Unfortunately, they have not been effective in these nonsyndromic epilepsies," said Jon Matthew Farber, MD.
Cannabis is useful and safe in epilepsy | Image credit: Author provided
A retrospective study in 36 children with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or another drug-resistant epilepsy (DRE) found that cannabidiol treatment reduced seizure frequency in two-thirds of patients and was not associated with adverse effects.
After participants had received prescription cannabidiol for 3 months, reduction in seizure frequency of all seizure types was measured by the Engel outcome scale: class I, free of disabling seizures; class II, rare disabling seizures; class III, worthwhile improvement; and class IV, no worthwhile improvement. According to electronic medical records, most LGS, DS, and DRE patients, namely 50%, 66.7%, and 40%, respectively, experienced a class III Engel outcome. Only 33% of participants experienced no clinical benefit from cannabidiol. In addition, most participants did not have any adverse effects from cannabidiol, though about one-third of LGS patients reported sleepiness. Investigators noted, however, that further studies are needed to determine the long-term efficacy and safety of cannabidiol.
Thoughts From Dr Farber:
There are, of course, concerns with long-term cannabidiol use, but that also is the case, if not more so, with traditional antiepileptics. Many of my patients with poorly controlled seizures have tried cannabidiols. Unfortunately, they have not been effective in these nonsyndromic epilepsies.
Reference:
Hovey SW, Jacobson JL. Efficacy of cannabidiol in pediatric patients: postmarket experience at a single center. J Pediatr Neurol. 2024;22(1):44-49. doi:10.1055/s-0043-57008
Seizures could be the cause of many sudden unexplained deaths in toddlers
January 9th 2024The study authors noted that without video evidence, seizures would not have been implicated in death investigations and that seizure-related deaths are underrecognized in patients with epilepsy and in those without.
FDA warns of serious potential reaction to levetiracetam and clobazam
November 30th 2023The reaction, called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), can start as a rash but can progress quickly, potentially resulting in injury to internal organs, hospitalization, and death.
Dietary therapies safe and efficient for treating drug-resistant epilepsy
February 7th 2023While treatment discontinuation because of adverse events was more likely when taking dietary therapies for treating childhood drug-resistant epilepsy, reduction of seizures and seizure freedom were significantly more common.
